α-Linolenic acid alleviates ovalbumin-induced allergic rhinitis in mice and modulates GPR120–NF-κB signaling Authors: Yulan Song, Fengyao Zhang, Yan Zhao, Ruofan Liu, Yan Feng Published: 2026 ABSTRACT Allergic rhinitis (AR) is a chronic inflammatory disease of the upper respiratory tract mediated by immunoglobulin E (IgE). Alpha-linolenic acid (ALA), an essential dietary omega-3 polyunsaturated fatty acid, has been proposed to possess anti-inflammatory and anti-allergic properties. However, research on the effects of ALA on AR and the underlying mechanisms remains limited. Therefore, we evaluated oral ALA intervention in an ovalbumin (OVA)-sensitized AR mouse model. Nasal symptoms were recorded, and nasal mucosal pathology was evaluated by hematoxylin and eosin staining. Goblet cell hyperplasia and mast cell accumulation were determined by periodic acid-Schiff and toluidine blue staining. Serum OVA-specific IgE and inflammatory cytokines (interferon-gamma [IFN-γ], interleukin-4 [IL-4], IL-6, and IL-1β) were measured by enzyme-linked immunosorbent assay. Additionally, pathway-related molecules in the nasal mucosa were identified by immunohistochemistry, qRT-PCR, and Western blotting. Results indicated that ALA significantly alleviated AR-like symptoms, improved nasal mucosal damage, reduced mast cell aggregation and goblet cell hyperplasia, decreased serum OVA-specific IgE, IL-4, IL-6, and IL-1β levels, and increased IFN-γ levels. Furthermore, ALA inhibited the NF-κB pathway and reduced the phosphorylation levels of IKK and NF-κB p65(Rela). These data indicate that ALA alleviates AR-associated inflammatory responses and may represent a potential therapeutic candidate for AR.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-53416-4. Introduction Allergic rhinitis (AR) is a prototypical mucosal allergic disorder characterized by epithelial barrier perturbation and a type 2-skewed inflammatory microenvironment in the nasal mucosa. Upon allergen re-exposure, local effector responses are exacerbated through cytokine and chemokine-induced recruitment and activation of inflammatory cells, accompanied by mucus hypersecretion and tissue remodeling. Currently, the clinical management of AR primarily depends on symptomatic drug therapy. Antihistamines and intranasal corticosteroids provide symptomatic relief; however, the efficacy and tolerability of these medications can vary. Allergen immunotherapy remains the only treatment that can slow disease progression1; however, it requires prolonged administration and exhibits significant interindividual variability in efficacy. These limitations underscore the need for mechanism-guided, mucosa-targeted strategies to mitigate AR-associated inflammation beyond symptomatic control. Nuclear factor κB (NF-κB) is a key transcription factor that regulates immune and inflammatory responses and serves as a central signaling hub in AR pathogenesis2–4. Multiple studies have indicated increased NF-κB activity in the nasal mucosa of patients with AR4,5. In murine and guinea pig AR models6,7, the inhibition of NF-κB reduces T helper 2 (Th2)/Th17-associated cytokine production and immunoglobulin E (IgE) levels, attenuates inflammatory cell infiltration, and improves symptom scores. Allergens can activate the Toll-like receptor 4 (TLR4)/interleukin-1 receptor-associated kinase 4 (IRAK4)/NF-κB pathway by initiating signaling through pattern recognition receptors (TLR4) on the epithelial and immune cell surface8. This activation induces the release of pro-inflammatory mediators and exacerbates the inflammatory cascade in AR. Furthermore, cross-linking of IgE–high-affinity receptor (FcεRI) complexes occupying the surface of basophils and/or mast cells leads to their activation, resulting in further perpetuation of type 2 inflammation, associated with increases in the levels of IL-4, IL-5, IL-13, and other cytokines and mediators9. This process is facilitated by NF-κB signaling, which further promotes type 2 responses and increases AR symptoms. In summary, NF-κB is a critical regulatory node in AR exacerbation and progression. G protein-coupled receptor 120 (GPR120), also known as free fatty acid receptor 4 (FFAR4), is a seven-transmembrane G protein-coupled receptor (GPCR)10. GPR120 is extensively expressed in multiple tissues11, including monocytes, macrophages, dendritic cells, and eosinophils. GPR120 signaling is highly active in macrophages (Raw264.7 cells) and adipocytes, where it exerts anti-inflammatory effects. β-arrestin2 is a crucial regulatory protein and scaffold molecule in the cytoplasm, where it typically interacts with heterotrimeric G proteins, serving as a key modulator and signal transducer for G protein-coupled receptors (GPCRs)12. Studies indicate that β-arrestin2 binds to ligand-activated GPR120, forming a GPR120/β-arrestin2 complex13. This complex further inhibits IKKβ activation and IκB phosphorylation, thereby reducing NF-κB nuclear translocation. Studies have reported that ginsenoside Rb2 and omega-3 polyunsaturated fatty acids can upregulate GPR120 expression in Raw264.7 cells14,15. Polyunsaturated fatty acids (PUFAs), especially the ω−3 and ω−6 families, are essential for human health and nutrition16. Omega-3 PUFAs are linked to epigenetic mechanisms in allergic diseases. Perinatal supplementation with omega-3 PUFAs can significantly reduce the risk of developing allergies17,18. Furthermore, foods containing omega-3 PUFAs have been shown to epigenetically affect key molecular and cellular components of the immune system early in life, potentially influencing the development of allergic disorders later in life19–21. Alpha-linolenic acid (ALA) is an essential dietary omega-3 polyunsaturated fatty acid that must be obtained from the diet22,23. ALA has anti-inflammatory, antioxidant24, and anti-cancer properties25, and is converted into eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Animal studies found that consuming a diet rich in ALA from flaxseed exhibited a significant reduction in typical behavioral symptoms in AR model mice, including sneezing and nose scratching26. Whether ALA regulates the GPR120/β-arrestin2/IKK/NF-κB pathway in the nasal mucosa remains unclear. However, there is currently no direct evidence. We therefore hypothesized that ALA alleviates AR by engaging the GPR120/β-arrestin2 pathway to suppress IKK/NF-κB signaling in the nasal mucosa. To test this hypothesis, we used an ovalbumin (OVA)-induced mouse model of AR to (i) evaluate the therapeutic effects of ALA on clinical-like nasal symptoms, mucosal pathology, and systemic allergic/inflammatory readouts (OVA-specific IgE and key cytokines), and (ii) investigate whether these effects are accompanied by modulation of the GPR120/β-arrestin2/IKK-NF-κB signaling cascade in nasal tissue. Together, this study aims to establish a mechanistically grounded rationale for using ALA as a potential adjunct strategy for AR. Results Behavioral scores of AR model mice From the first day of challenge, mice in the OVA group exhibited significant symptoms, including sneezing, nasal scratching, and rhinorrhea. These symptoms progressed in severity with increasing OVA challenge frequency. By day 34, nasal symptom scores in the sham group remained consistently below 5, whereas scores in the OVA group exceeded 5, indicating successful establishment of the AR model (see Fig. 1 for the experimental model timeline). Following treatment, the ALA group exhibited a dose-dependent reduction in AR symptoms. Compared with the OVA group, significant improvements were first observed on day 25 in the high-dose ALA group (32 mg/kg; p < 0.05), on day 29 in the loratadine (Lora) group and the medium-dose ALA group (16 mg/kg; p < 0.05), and on day 32 in the low-dose ALA group (4 mg/kg; p < 0.05). By the end of the experiment (day 34), sneezing, nose-rubbing, and nasal discharge were significantly reduced in all ALA dose groups and in the Lora group compared with the OVA group (p < 0.05). Data are presented in Fig. 2. Fig. 1Schematic of the sensitization and drug treatment protocol. ALA, Alpha-linolenic acid; Lora, loratadine; OVA, ovalbumin. Schematic of the sensitization and drug treatment protocol. ALA, Alpha-linolenic acid; Lora, loratadine; OVA, ovalbumin. Fig. 2Behavioral assessment of AR symptoms (n = 10/group). (A) Total nasal symptom scores across the challenge period. (B) Nose-rubbing (nasal scratching). (C) Sneezing counts on the final day of the OVA challenge. Data are presented as the mean ± SD, n = 10 mice/group. “*” denotes a comparison versus the sham group (*p < 0.05, **p < 0.01, ***p < 0.001). “#” indicates a comparison versus the OVA group (#p < 0.05, ##p < 0.01, ###p < 0.001). OVA, ovalbumin; ALA, Alpha-linolenic acid; Lora, loratadine; SFAR, score for allergic rhinitis. Behavioral assessment of AR symptoms (n = 10/group). (A) Total nasal symptom scores across the challenge period. (B) Nose-rubbing (nasal scratching). (C) Sneezing counts on the final day of the OVA challenge. Data are presented as the mean ± SD, n = 10 mice/group. “*” denotes a comparison versus the sham group (*p < 0.05, **p < 0.01, ***p < 0.001). “#” indicates a comparison versus the OVA group (#p < 0.05, ##p < 0.01, ###p < 0.001). OVA, ovalbumin; ALA, Alpha-linolenic acid; Lora, loratadine; SFAR, score for allergic rhinitis. ALA restores type 1/type 2 balance by suppressing type 2 responses and enhancing type 1 activity The serum levels of IFN-γ, IL-4, IL-6, IgE, and IL-1β were measured by ELISA. Compared with the sham group, the OVA group exhibited significantly increased serum levels of IL-4, IL-6, IgE, and IL-1β (p < 0.05), whereas IFN-γ levels were significantly reduced (p < 0.05). Following treatment with ALA or loratadine, all treatment groups exhibited a significant reduction in IL-4, IL-6, IgE, and IL-1β levels compared to the OVA group (p < 0.05; Figs. 3B − E), while IFN-γ levels were significantly increased (p < 0.05; Fig. 3A). Notably, these changes in circulating inflammatory mediators were consistent with transcriptional modifications observed in the nasal mucosa. Specifically, compared with the sham group, the OVA group exhibited significantly downregulated Ifng (IFN-γ gene name) mRNA expression and upregulated mRNA expression of Il4 (IL4 gene name), Il6, and Il1b (IL-1β gene name) in the nasal mucosa (p < 0.05; Figs. 3F − I). In contrast, ALA treatment significantly upregulated Ifng mRNA and downregulated Il4, Il6, and Il1b mRNA expression compared with the OVA group (p < 0.05). In summary, ELISA and qPCR results consistently indicate that ALA attenuated OVA-induced inflammation in a dose-dependent manner, with the high-dose ALA group exhibiting the most significant improvement. Fig. 3Changes in inflammatory cytokines in the AR mice model following ALA treatment. Serum levels of (A) IFN-γ, (B) IL-6, (C) IgE, (D) IL-1β, and (E) IL-4 were measured through ELISA (n = 6/group). The mRNA expression levels of inflammatory cytokines (F) Il6 (IL-6 gene name), (G) Il1b (IL-1β gene name), (H) Ifng (IFN-γ gene name), (I) Il4 (IL-4 gene name) in mouse nasal mucosa were determined through qRT-PCR across different groups (n = 3/group). Data are presented as the mean ± SD. “*” indicates a comparison versus the sham group (*p < 0.05, **p < 0.01, ***p < 0.001). “#” indicates a comparison versus the OVA group (#p < 0.05, ##p < 0.01, ###p < 0.001). OVA, ovalbumin; ALA, Alpha-linolenic acid; Lora, loratadine. Changes in inflammatory cytokines in the AR mice model following ALA treatment. Serum levels of (A) IFN-γ, (B) IL-6, (C) IgE, (D) IL-1β, and (E) IL-4 were measured through ELISA (n = 6/group). The mRNA expression levels of inflammatory cytokines (F) Il6 (IL-6 gene name), (G) Il1b (IL-1β gene name), (H) Ifng (IFN-γ gene name), (I) Il4 (IL-4 gene name) in mouse nasal mucosa were determined through qRT-PCR across different groups (n = 3/group). Data are presented as the mean ± SD. “*” indicates a comparison versus the sham group (*p < 0.05, **p < 0.01, ***p < 0.001). “#” indicates a comparison versus the OVA group (#p < 0.05, ##p < 0.01, ###p < 0.001). OVA, ovalbumin; ALA, Alpha-linolenic acid; Lora, loratadine. Alterations in the NF-κB signaling pathway were observed following ALA intervention Immunohistochemical analysis of IKK, P-IKK, NF-κB p65, and p-p65 expression in mouse nasal mucosal tissue was performed using light microscopy combined with ImageJ software (Fig. 4). Because phosphorylation of IKK and p65 is generally associated with activation of NF-κB-related signaling, p-IKK and p-p65 were used in this study as indicators of pathway activation. The results indicated that p65, IKK, and P-IKK were primarily expressed in the cytoplasm, while p-p65-positive staining was predominantly observed in the nuclear region; positive staining appeared as brownish-yellow signals (Fig. 4). Compared with the sham group, IKK, P-IKK, and p-p65 expression levels were significantly upregulated in the OVA group (p < 0.05; Figs. 4B − E). Conversely, all ALA intervention groups exhibited a significant downregulation in IKK, P-IKK, and p-p65 expression compared with the OVA group (p < 0.05), with the high-dose ALA group demonstrating the most significant decrease. In contrast, total p65 staining exhibited no significant difference among groups, suggesting that ALA primarily affected p65 phosphorylation rather than total p65 abundance. Fig. 4Alterations in the NF-κB signaling pathway after ALA intervention (n = 3/group). (A) Immunohistochemistry staining results. Quantitative analysis of protein expression using the H-Score method (scale bar = 20 μm). Expression levels of (B) IKK, (C) P-IKK, (D) P‐p65, and (E) p-p65/p65. Data are presented as the mean ± SD, n = 3. “*” denotes a comparison versus the sham group (*p < 0.05, **p < 0.01, ***p < 0.001). “#” denotes a comparison versus the OVA group (#p < 0.05, ##p < 0.01, ###p < 0.001). ALA, Alpha-linolenic acid; Lora, loratadine; OVA, ovalbumin; IKK, IκB kinase; NF-κB, Nuclear factor κB; P‐, phosphorylated. Representative negative control images obtained by omission of the primary antibody are provided in Supplementary Figure S2. Alterations in the NF-κB signaling pathway after ALA intervention (n = 3/group). (A) Immunohistochemistry staining results. Quantitative analysis of protein expression using the H-Score method (scale bar = 20 μm). Expression levels of (B) IKK, (C) P-IKK, (D) P‐p65, and (E) p-p65/p65. Data are presented as the mean ± SD, n = 3. “*” denotes a comparison versus the sham group (*p < 0.05, **p < 0.01, ***p < 0.001). “#” denotes a comparison versus the OVA group (#p < 0.05, ##p < 0.01, ###p < 0.001). ALA, Alpha-linolenic acid; Lora, loratadine; OVA, ovalbumin; IKK, IκB kinase; NF-κB, Nuclear factor κB; P‐, phosphorylated. Representative negative control images obtained by omission of the primary antibody are provided in Supplementary Figure S2. ALA-treated groups showed upregulation of GPR120/β-arrestin2 and suppression of NF-κB-related signaling in nasal mucosa RT-qPCR was used to determine mRNA expression levels of Ffar4 (GPR120 gene name), Arrb2 (β-arrestin2 gene name), and Rela (NF-κB gene name) in the nasal mucosa of mice from different experimental groups (Fig. 5). Compared with the sham group, the OVA group exhibited significantly downregulated mRNA expression of GPR120 and β-arrestin2, whereas p65 mRNA expression was significantly upregulated (p < 0.05; Figs. 5A − C). In contrast, compared with the OVA group, mRNA expression of GPR120 and β-arrestin2 was significantly upregulated, while p65 mRNA levels were significantly decreased. Western blotting analysis was performed to determine IKK, P-IKK, p-p65, p65, β-arrestin2, and GPR120 expression in the nasal mucosa of each group (Fig. 5). GPR120 was normalized to β-tubulin, whereas the other proteins were normalized to β-actin. Compared with the sham group, OVA stimulation significantly upregulated the protein expression of IKK, P-IKK, and p-p65 (p < 0.05; Figs. 5E − G). ALA intervention dose-dependently reversed these changes, significantly downregulating the expression of these proteins (p < 0.05). Furthermore, compared with the OVA group, GPR120 protein expression increased in medium and high-dose ALA treatment groups, whereas β-arrestin2 protein expression was significantly increased only in the high-dose ALA group (p < 0.05; Figs. 5H − J), suggesting a potential association between ALA treatment and modulation of GPR120-related signaling. Notably, total p65 protein expression did not differ significantly among groups, indicating that the treatments primarily affected p65 phosphorylation rather than total protein abundance. Fig. 5Gene and protein Expression Changes in Inflammation-Related Signaling Pathways. (A) Arrb2 (β-arrestin2 gene name), (B) Ffar4 (GPR120 gene name), and (C) Rela (NF-κB gene name) in mouse nasal mucosal epithelial tissues across different groups(n = 3/group). (D) Western blotting analysis of (E) IKK, (F) P-IKK, (G) p-p65, (H) p-p65/p65, (I) GPR120 protein and (J) β-arrestin2 levels. Data are presented as the mean ± SD, (n = 4/group). “*” denotes a comparison versus the sham group (*p < 0.05, **p < 0.01, ***p < 0.001). “#” denotes a comparison versus the OVA group (#p < 0.05, ##p < 0.01, ###p < 0.001). Full-length uncropped blots are presented in Supplementary Figure S1. ALA, Alpha-linolenic acid; Lora, loratadine; OVA, ovalbumin; IKK, IκB kinase; NF-κB, Nuclear factor κB; P-, phosphorylated. Gene and protein Expression Changes in Inflammation-Related Signaling Pathways. (A) Arrb2 (β-arrestin2 gene name), (B) Ffar4 (GPR120 gene name), and (C) Rela (NF-κB gene name) in mouse nasal mucosal epithelial tissues across different groups(n = 3/group). (D) Western blotting analysis of (E) IKK, (F) P-IKK, (G) p-p65, (H) p-p65/p65, (I) GPR120 protein and (J) β-arrestin2 levels. Data are presented as the mean ± SD, (n = 4/group). “*” denotes a comparison versus the sham group (*p < 0.05, **p < 0.01, ***p < 0.001). “#” denotes a comparison versus the OVA group (#p < 0.05, ##p < 0.01, ###p < 0.001). Full-length uncropped blots are presented in Supplementary Figure S1. ALA, Alpha-linolenic acid; Lora, loratadine; OVA, ovalbumin; IKK, IκB kinase; NF-κB, Nuclear factor κB; P-, phosphorylated. Histopathological changes in the nasal mucosa of AR mice following ALA treatment H&E staining revealed that the nasal mucosal epithelium in the sham group mice maintained an intact architecture, with well-organized cilia and no significant inflammatory cell infiltration in the submucosal layer (Fig. 6A). In contrast, the OVA model group exhibited disrupted epithelial arrangement and loss of continuity, accompanied by extensive submucosal infiltration of inflammatory cells, tissue edema, vascular dilation, and focal epithelial detachment. Intervention with ALA ameliorated nasal mucosal pathology in a dose-dependent manner. All ALA-treated groups exhibited reduced inflammatory cell infiltration and progressive restoration of epithelial integrity. The numbers of inflammatory cells, goblet cells, and mast cells were quantified by manual counting in 3 − 5 selected fields with intact tissue structure per section at the same magnification, and the average values were used for statistical analysis. Furthermore, the positive control drug, loratadine, demonstrated protective effects on nasal mucosal injury. PAS and TBS staining further indicated a significant increase in the numbers of goblet cells and mast cells in the OVA group (Figs. 6B − C), staining purple-red and purple, respectively. Following ALA treatment, the number of both cell types decreased progressively with increasing dosage, suggesting a dose-dependent inhibitory effect on inflammatory cell accumulation. Regarding mast cell suppression, loratadine, a second-generation antihistamine, exhibited significant efficacy comparable to that of the high-dose ALA group. Fig. 6Pathological changes in the nasal mucosa of ALA-treated mice with allergic rhinitis(n = 3/group). (A) Histopathological alterations in the nasal mucosal epithelium were examined using Hematoxylin and eosin staining (scale bar = 50 μm) (B) Periodic acid-Schiff staining was employed to identify the goblet cells in the nasal mucosa (red arrows; scale bar = 50 μm). (C) Toluidine blue staining was utilized to visualize the mast cells of the nasal mucosa (red arrows; scale bar = 50 μm). ALA, Alpha-linolenic acid; Lora, loratadine; OVA, ovalbumin. Pathological changes in the nasal mucosa of ALA-treated mice with allergic rhinitis(n = 3/group). (A) Histopathological alterations in the nasal mucosal epithelium were examined using Hematoxylin and eosin staining (scale bar = 50 μm) (B) Periodic acid-Schiff staining was employed to identify the goblet cells in the nasal mucosa (red arrows; scale bar = 50 μm). (C) Toluidine blue staining was utilized to visualize the mast cells of the nasal mucosa (red arrows; scale bar = 50 μm). ALA, Alpha-linolenic acid; Lora, loratadine; OVA, ovalbumin. Discussion In this study, we found that ALA can improve AR-like symptoms in an OVA-induced mouse model. ALA alleviated allergic symptoms by reducing sneezing and nose rubbing. Histological analysis indicated that ALA treatment attenuated inflammatory cell infiltration in the nasal mucosa and reduced goblet cell hyperplasia and mast cell accumulation. In serum, IgE and type 2-associated inflammatory cytokines were decreased, whereas IFN-γ levels increased. At the mechanistic level, ALA treatment was associated with increased GPR120 and β-arrestin2 expression, together with reduced IKK/NF-κB-related signaling in the nasal mucosa. These effects were generally dose-dependent, and the high-dose ALA group demonstrated effects comparable to those of the Lora group. ALA reduces type 2-induced allergic inflammation in AR. Type 1/Type 2 immune imbalance is a key mechanism in AR pathogenesis27–29. Type 1 cells mediate cellular immune responses by secreting cytokines, including IL-2 and IFN-γ30, whereas type 2 cells drive humoral immunity and B-cell antibody production by secreting cytokines including IL-4, IL-5, IL-6, IL-10, and IL-1331. Type 2 cytokines promote IgE synthesis. IgE stimulates the release of multiple inflammatory mediators by binding to FcεRI on effector cells (mast cells and eosinophils), thereby exacerbating allergic reactions32. Conversely, type 1 cytokine IFN-γ suppresses IgE production33, thereby providing a physiological counterbalance to type 2 dominance. NF-κB is a key transcription factor that regulates immune and inflammatory responses and can amplify allergic inflammation. In this study, compared with the OVA group, ALA treatment significantly downregulated the expression levels of p65 (Rela) and pro-inflammatory factors regulated by NF-κB (IL-6 and IL-1β) in the nasal mucosa of mice. Additionally, OVA-specific IgE and IL-4 levels decreased, whereas IFN-γ expression increased. These findings suggest that ALA may alleviate AR by suppressing NF-κB-related signaling, reducing pro-inflammatory mediators, and helping to restore type 1/type 2 immune balance. These changes were accompanied by reduced inflammatory cell infiltration, decreased goblet cell hyperplasia, and alleviated mucosal injury, indicating that ALA improved the local allergic inflammatory microenvironment in AR34. GPR120 is a crucial fatty acid receptor10, with long-chain polyunsaturated fatty acids serving as its primary ligands, particularly omega-3 polyunsaturated fatty acids exhibiting a potent agonist35. In macrophages and adipocytes, GPR120 signaling exerts anti-inflammatory effects, improving insulin sensitivity by reducing chronic inflammation in peripheral tissues. Studies indicate that β-arrestin2 binds to IκBα and IKK, inhibiting CK2 and IKK phosphorylation of IκBα, thereby inhibiting NF-κB activation36. In this study, compared with the OVA-induced model group, the ALA treatment groups exhibited increased GPR120 protein and mRNA levels, accompanied by increased β-arrestin2 protein and mRNA levels. These findings suggest that ALA may reduce NF-κB pathway activation, accompanied by increased GPR120 expression and β-arrestin2 upregulation. ALA also reduced IKK, p-IKK, and p-p65 expression without affecting total p65 abundance. Collectively, these findings suggest that modulation of GPR120-related signaling may be involved in the inhibitory effect of ALA on IKK/NF-κB-related signaling. In summary, our results show an association between ALA treatment and changes in GPR120/IKK/NF-κB-related signaling in the nasal mucosa. We also observed shifts in type 1 and type 2 cytokines, along with improved tissue outcomes. These effects appeared in a dose-related pattern. This study has several limitations. First, although ALA treatment was associated with upregulation of GPR120/β-arrestin2 expression and attenuation of IKK/NF-κB-related signaling, a causal relationship between these changes and the protective effects of ALA cannot yet be definitively established, as no GPR120 inhibition or knockout experiments were performed. Second, because this study did not employ hypothesis-free approaches such as RNA sequencing or proteomic analysis, it may not have fully identified all relevant pathways or molecular networks underlying the protective effects of ALA. Third, the findings were primarily derived from an OVA-induced mouse model of allergic rhinitis, and their translational relevance to humans requires further validation in more clinically relevant systems, such as human tissues, primary cells, or organoid models. Finally, because previous studies suggest that female mice are generally more sensitive than males in terms of allergic and inflammatory responses, only female mice were included in this study; therefore, the current findings cannot be directly extrapolated to male animals. Future studies including both male and female animals are needed to further determine whether the effects of ALA are sex dependent. This study found that the time to onset of efficacy differed across ALA dose groups in animal behavioral evaluation. This observation suggests that GPR120 activation can involve a threshold effect. Accordingly, higher ALA doses can significantly inhibit NF-κB signaling, which is consistent with earlier symptom improvement. Additionally, compared with EPA and DHA, which are primarily derived from fish oil, ALA is more extensively available from plant sources. This makes ALA a practical alternative for increasing omega-3 fatty acid intake among vegetarians and in regions with limited access to fish oil. ALA has the potential to serve as an adjunct intervention in conjunction with conventional medications, as AR is a chronic condition requiring long-term management. This method has the potential to decrease dependence on symptomatic medications while simultaneously preserving therapeutic benefits. However, further studies are required to determine the optimal dosage, evaluate long-term safety, and confirm clinical effectiveness. Conclusions ALA alleviated AR-like symptoms and improved nasal mucosal pathology in an OVA-induced mouse model, accompanied by reduced allergic and inflammatory mediators, as well as suppression of IKK/NF-κB-related signaling in nasal tissue. Additionally, ALA treatment was associated with increased GPR120 and β-arrestin2 expression, suggesting a potential association between ALA treatment and modulation of GPR120-related signaling. However, without GPR120 inhibition/knockout experiments, causality cannot be definitively established. Further studies are needed to validate the underlying mechanism, define target cells, and evaluate optimal dosing and clinical relevance. Materials and methods Reagents: α-Linolenic acid (ALA), purity ≥ 98%, was obtained from Baoji Herbest Bio-Tech Co.,Ltd. (Cat. No. HA061919). OVA was purchased from Sigma-Aldrich (Merck KGaA), USA. Loratadine tablets were received from Bayer Pharmaceuticals (Shanghai) Co., Ltd. (Batch No.: JS12630). The aluminum hydroxide was dissolved in normal saline solution. Establishment of animal models This research protocol was granted approval by the Ethics Committee at The First Hospital of Shanxi Medical University (Approval No.: DWLL-2025-011). All experiments were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals37. A total of 60 female BALB/c mice (6–8 weeks old) were purchased from Nanjing Junke Biotechnology Co., Ltd. Mice were maintained at 25 ± 1 °C with 45%−55% relative humidity under a 12-h light/12-h dark cycle, with free access to food and water. Before the experiment, the mice were acclimated for one week according to standard procedures to ensure adaptation to the new living environment. The mice underwent a 34-day intervention following a 1-week acclimation period, for a total study duration of 41 days. During this period, regular checks were conducted to ensure the mice remained in good health and received adequate care. Based on a literature review and our prior experience, we successfully established an AR mouse model38,39. The mice were randomly divided into six groups: (I–III) ALA treatment groups (4, 16, and 32 mg/kg); (IV) positive control group (loratadine, 1.5 mg/kg); (V) sham group (vehicle/saline); (VI) OVA group (OVA-sensitized and challenged). The modeling procedure was as follows: On days 0, 7, and 14, the mice were intraperitoneally injected with 0.1 mL of aluminum hydroxide solution (1 mg/mL) containing 100 µg of OVA for sensitization. From days 21 to 34, mice were intranasally challenged once daily with OVA (20 µL, 10 mg/mL). During the same period (days 21–34), mice received oral administration of ALA (dissolved in 0.01% ethanol), loratadine, or vehicle (0.01% ethanol in saline), according to group assignment. ALA dosing was selected based on preliminary studies and determined using human-animal dose equivalence conversion. The concentration and duration of the intervention were determined based on the preliminary study conducted by Ding et al.40. The sham group received matched volumes of vehicle instead of OVA during both sensitization and challenge, with volumes consistent with those used in OVA-treated groups. For nasal challenge, the pre-prepared OVA solution was administered intranasally using a 20 µL pipette, delivered dropwise to minimize distress and reduce the risk of aspiration. On the final day of the experiment, mice were deeply anesthetized with sodium pentobarbital (50 mg/kg, intraperitoneal injection) and euthanized by cervical dislocation. After euthanasia, nasal mucosa and blood samples were collected. To confirm cessation of vital signs, respiration and heartbeat were observed, pupillary reflexes were examined, and skin temperature, heart rate, and pulse changes were assessed through tactile evaluation. Animals were monitored closely throughout the study; no unexpected deaths occurred. Humane endpoints were applied when necessary to minimize pain and distress, including severe health deterioration, untreatable conditions, significant abnormal behavior, or when experimental objectives had been achieved without further viable data collection. No animals met criteria for premature euthanasia, and all mice completed the protocol as planned in accordance with animal welfare and ethical standards. AR symptom scoring From day 21 to day 34, the frequency of sneezing and nasal rubbing, as well as the intensity of nasal discharge, were recorded for each group for 30 min by an observer blinded to group assignments. A total score exceeding 5 points indicated effective sensitization41. The AR score was calculated by summing the scores for sneezing, nose-rubbing, and nasal discharge. Non-parametric tests were used to analyze the total scores. The detailed scoring criteria are provided in Supplementary Table S3. Histopathological examination of the nasal mucosa The mouse nasal mucosal epithelium was collected and fixed in 4% paraformaldehyde (Cat. No. DF0135, Beijing Regene Biotech Co., Ltd.) at 4 °C for 24 h. After fixation, the specimens were decalcified in 10% EDTA buffer (Cat. No. E1171, Beijing Suolaibao Technology Co., Ltd.) for 14 days. Following dehydration, the sample was embedded in paraffin to form a paraffin block. Each embedded wax block was pre-cooled at − 20 °C for 30 min, sectioned into 5-µm thick slices, and dried in an oven at 60 °C for 2 h. Subsequently, the sections were dewaxed using a xylene-ethanol gradient, followed by staining at room temperature with toluidine blue (TBS), periodic acid-Schiff (PAS), and hematoxylin and eosin (H&E). TBS (1%), PAS, and H&E (Cat. No. G3668, G1281, and G1120, respectively) were obtained from Beijing Solarbio Technology Co., Ltd. H&E staining The tissue sections were dewaxed twice with xylene and then rehydrated through a gradient from 100% to 75% ethanol, with each concentration being immersed for 3 min, followed by a 2 min wash with distilled water. The sections were stained with hematoxylin for 5 min, washed with distilled water, and differentiated in a differentiation solution for 30 s. Subsequently, they were washed three times with tap water, each wash lasting 5 min. The sections were counterstained with eosin for 1 min, excess stain was removed, and they were immediately dehydrated through another ethanol gradient series from 75% to 100% (with 3 s immersion at each concentration). This was followed by a 1-min immersion in 100% ethanol, two 1-min immersions in xylene, and finally sealed with neutral resin. TBS staining Following the same dewaxing and rehydration procedure used for H&E staining, the sections were immersed in TBS for 10 min, washed with distilled water for 1 min, and gently blotted with filter paper. The staining intensity was controlled microscopically until mast cells appeared violet-blue, and the background exhibited pale blue. Subsequently, the sections were immediately dehydrated in 95% ethanol for 5 s, immersed twice in absolute ethanol (1 min each) and xylene, and sealed with neutral resin. Pathological changes were observed under an optical microscope. PAS staining Following the same dewaxing and rehydration procedure used for H&E staining, the sections were initially washed in tap water for 3 min and then washed twice in distilled water. Then, the periodate solution was added and incubated for 5 min at room temperature. The sections were washed with tap water and then washed twice with deionized water. Schiff staining solution was applied and incubated in the dark for 10 min. After rinsing with deionized water for 10 min, the nuclei were counterstained with hematoxylin for 1 min, acidified with acid differentiation solution for 3 s, and finally washed in tap water for 10 min. The sections were dehydrated with graded ethanol, washed with 100% xylene, and sealed with neutral resin. ELISA Blood was collected from the mouse’s eyes. The blood was temporarily stored on ice and then centrifuged at 1,800 × g for 15 min at room temperature to separate serum. The levels of the following cytokines in serum samples were measured using specific ELISA kits from Jianglai Biotechnology Co., Ltd. following the manufacturer’s guidelines: IL-6 (Cat. No. JL20268), IL-1β (Cat. No. JL18442), IL-4 (Cat. No. JL20266), IFN-γ (Cat. No. JL10967), and OVA-sIgE (Cat. No. JL55065). Each serum sample was measured in technical triplicate. Immunohistochemistry staining Immunohistochemistry was performed to detect the expression levels of NF-κB (p65), phosphorylated NF-κB (p-p65), IκB kinase (IKK), and phosphorylated IKK (P-IKK) in the nasal mucosal epithelial tissues of mice. Paraffin sections were deparaffinized, rehydrated, and placed in 0.01 M sodium citrate buffer (pH 6.0). For p-p65, the antigen was retrieved using an EDTA retrieval solution (pH 9.0) and heat-induced in a pressure cooker. After reaching 100 °C, the temperature was maintained for 2 min, followed by cooling to room temperature. The tissues were treated with a freshly prepared 3% hydrogen peroxide solution in methanol and incubated in the dark for 10 min to block endogenous peroxidase. Subsequently, sheep serum was used for blocking at room temperature for 20 min. After removing the blocking serum, the following primary antibodies were added: IKK: Cat. No. WL0053, 1:100, Shenyang Wanlei Biotechnology Co., Ltd.; p65: Cat. No. 10745-1-A P, 1:100, Wuhan Sanying Biotechnology Co., Ltd.; P-IKK: Cat. No. TP56290S, 1:100; and p-p65: Cat. No. TA2006S, 1:100, both from Abimart Pharmaceutical Technology (Shanghai) Co., Ltd., and incubated overnight at 4 °C. The next day, the primary antibody was removed, and the secondary antibody, goat anti-mouse/rabbit IgG polymer, was added and incubated at room temperature. Subsequently, a freshly prepared DAB chromogenic solution was used for observation. The samples were washed with tap water to terminate the reaction. The sections were stained with hematoxylin for 1 min and then washed with tap water for 10 min to restore the blue color. Finally, the sections were dehydrated with graded ethanol, washed with xylene, and sealed with neutral resin. All sections were scanned using the same scanner and evaluated at the same magnification. For each section, 3 − 5 fields with intact tissue structure were selected for quantitative analysis. The expression levels of target protein were quantified using ImageJ-win 64 software (NIH). Although the analysis was not formally conducted in a blinded manner, the same image selection and analysis criteria were applied to all samples to reduce potential bias. Quantitative analysis of protein expression was performed using the H-Score method. The H-Score calculation formula is defined as follows: (weak staining percentage × 1) + (moderate staining percentage × 2) + (strong staining percentage × 3). This scoring system yields a potential range from 0 to 300. Reverse transcription-quantitative PCR (RT-qPCR) The mouse nasal mucosal tissues stored at − 80 °C were thawed. Total RNA was extracted using the TriQuick Total RNA Extraction Kit (Cat. No. R1100, Beijing Solarbio Technology Co., Ltd.). The tissues were thoroughly lysed using a tissue homogenizer. Then, chloroform was added, the mixture was vortexed to mix, and centrifuged at 12,000 × g for 15 min at 4 °C. The supernatant was aspirated, mixed with an equal volume of isopropanol, and incubated at − 20 °C overnight for RNA precipitation. RNA pellet was obtained by centrifuging at 12,000 × g for 10 min at 4 °C. The extracted RNA was reverse-transcribed into cDNA using an RT kit (Cat. No. RR036A, Takara Bio, Inc.). The amplification conditions were as follows: 37 °C for 15 min, 85 °C for 15 s, followed by storage at 16 °C. RT-qPCR was performed using 2× M5 HiPer SYBR Premix Es Taq (Cat. No. MF787-01, Beijing PolyMei Biotechnology Co., Ltd.). The relative gene expression levels were calculated using the 2–ΔΔCq method42. GAPDH was used as an internal control. The primer sequences are provided in Supplementary Table S2. Western blotting analysis Total protein was extracted from mouse nasal mucosal tissues using RIPA lysis buffer. Protein concentration was quantified using the BCA Kit (Cat. No. AR0146; Boster Biological Technology), following the manufacturer’s protocol. After normalizing the total protein concentration, the samples were mixed with 5× SDS-PAGE loading buffer. Subsequently, the proteins were denatured by heating them in a metal bath at 100 °C for 10 min. The denatured proteins were separated by 10% SDS-PAGE and transferred to PVDF membranes through wet transfer over 1.5–2 h. After transfer, PVDF membranes were blocked with 10% skim milk powder at room temperature for 2 h. The blocked membranes were incubated overnight at 4 °C with the following primary antibodies: p65 (Cat. No. 10745-1-AP, 1:5000), β-actin (Cat. No. P60709, 1:10000), from Wuhan Sanying Biotechnology Co., Ltd.; β-tubulin (Cat. No. RA0002, 1:1000, Nature Biosciences); β-arrestin2 (Cat. No. A63739, 1:1000, Nature Biosciences); GPR120 (Cat. No. sc-390752, 1:1000, Santa Cruz Biotechnology, Inc.); IKK (Cat. No. T55660S, 1:1000) from Abmart Pharmaceutical Technology (Shanghai) Co., Ltd.; P-IKK (Ser176) (1:1000); p-p65 (Ser536) (1:1000). Following washing, the membranes were incubated with the corresponding secondary antibody (Cat. No. AS014, 1:8000, ABclonal Biological Technology) at room temperature for 2 h. After thorough washing, the signal was developed using the Ultra-Sensitive ECL Chemiluminescence Reagent Kit (Cat. No. BMU102, Abbkine Scientific Co., Ltd.). Protein optical density was measured using ImageJ-win64 software. Statistical analysis Behavioral outcomes were analyzed using n = 10 mice per group. ELISA was performed using n = 6 biological replicates per group. For qRT-PCR, immunohistochemistry, and Western blotting, n = 3, 3, and 4 biological replicates per group, respectively, were randomly selected from the cohort. Statistical analyses were performed using GraphPad Prism 10.1.2. Data are presented as mean ± standard deviation (SD). Normality was assessed before statistical comparisons. For comparisons among more than two groups, one-way ANOVA followed by Tukey’s multiple comparisons test was used when data were normally distributed. When data were not normally distributed, the Kruskal-Wallis test followed by Dunn’s multiple comparisons test was applied. SFAR scores were analyzed using the Kruskal-Wallis test with Dunn’s post hoc test. A p-value < 0.05 was considered statistically significant. Electronic Supplementary Material Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1 Supplementary Material 2 Supplementary Material 2